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Abstract 
Escherichia coli and Salmonella enterica are Gram-negative bacteria that are among the 
leading causes of gastrointestinal tract infections. These bacteria interact with mammalian hosts 
by using a type III secretion system (T3SS) to secrete effectors into host cells. NleB and SseK 
are two E. coli and Salmonella effector orthologs that are unusual glycosyltransferases. They 
glycosylate host protein substrates on arginine residues with N-acetyl glucosamine (GlcNAc) to 
inhibit the function of host proteins involved in the innate immune response. Originally, it was 
thought that the effectors are inactive within the bacterium and fold into their active 
conformations only after being secreted. However, mass spectrometry experiments to identify 
glycosylation substrates of NleB orthologs challenged this dogma, providing the premise for the 
first part of this thesis. Mass spectrometry suggested that the septum site-determining protein 
used in cell division, MinC, and the peptidyl-prolyl cis-trans isomerase protein that promotes 
bacterial stress tolerance and virulence, FklB, were glycosylated by NleB on arginine residues 
R107 and R129, respectively. Data from in vitro assays suggested that NleB glycosylated the 
arginine residues of both bacterial substrates, but when tested further, MinC and FklB were not 
confirmed to be glycosylated in Citrobacter rodentium, S. enterica, enteropathogenic E. coli 
(EPEC), or enterohemorrhagic E. coli (EHEC). This could be due to the MinC and FklB bacterial 
proteins being false positives when the mass spectrometry experiments were completed. Despite 
this negative data, intra-bacterial glycosylation of the mammalian substrates, the fas-associated 
protein with death domain (FADD), glyceraldehyde 3-phosphate dehydrogenase (GAPDH), and 
tumor necrosis factor receptor type 1-associated death domain protein (TRADD), were then 
studied. Results detected that all three mammalian substrates were glycosylated by NleB on 
arginine residues R177, R197/R200, and R235, respectively, and that FADD was a stronger 
  
glycosylation target of NleB than GAPDH and TRADD. The second part of this thesis also 
explores secretion through the T3SS, but instead of secreting a whole effector, camelid 
nanobodies were fused with signal sequences 20 amino acids in length from effectors that are 
naturally secreted and examined.  An attenuated bacterium with an engineered T3SS was created 
to secrete the nanobody fusions, and in vivo analyses before and after precipitation were 
completed using C. rodentium and E. coli. Nanobodies fused with effector signal sequences 
upstream from the camelid signal sequences were expressed, but not secreted through the T3SS. 
This concludes that a 20 amino acid signal sequence does not promote the secretion of the 
nanobodies through a T3SS. 
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Chapter 1 - Introduction 
 1.1 Motivation 
Medicine and technology are continuously advancing every day, yet microbial 
contamination and the complications that come with it remain a challenge around the world. 
Among some of the most significant microbes that cause public health problems are Gram-
negative bacteria with the most prevalent group being the family Enterobacteriaceae (Oliveira 
and Reygaert, 2019). One reason for this is the high resistance to antibiotics. Treatment of 
serious nosocomial infections becomes more problematic as resistance arises and spreads, 
putting the population at risk to being refractory to treatment with many of the currently 
available antibiotics (Paterson, 2006). Another reason why the Enterobacteriaceae family is 
important is due to the high impact it has on public health, most notably seen through bacterial 
food-borne pathogens. Clinical microbiology, infectious diseases, and the community’s well-
being are all influenced greatly by some of the bacteria within this group (Baylis, Uyttendaele, 
Joosten, and Davies, 2011). These reasons alone would suggest that further research into the 
Enterobacteriaceae family would be merited. 
Extensive research has focused on the Enterobacteriaceae family in the past, but recent 
advances in science have uncovered expansions in this area. This includes various mechanisms 
of the bacteria, emerging pathogenic strains, virulence characteristics, survival and persistence of 
the bacteria, and changes in the bacterial taxonomy (Baylis et al., 2011). One of the main focuses 
in science is how to prevent Enterobacteriaceae infection, and more specifically in this study, 
how to prevent Escherichia coli and Salmonella from infecting host cells and evading the host’s 
immune response. To obtain the answer, different approaches on inhibiting the effectors of these 
microbes must be meticulously analyzed. 
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 1.2 Background 
The Host Immune Response. Knowledge of the immune system has been steadily 
increasing throughout recent years, yet its complexity and pervasiveness still leave room for new 
discoveries. The basis lies in the host’s recognition of normal, structural components when 
abnormal cells are eliminated, and in the recognition of potential pathogens when protection 
against invading microbial infections is needed (Medzhitov, 2007). The immune system has 
three different stages that help with this basis of recognition and protection. The first mechanism 
of defense is physical barriers such as skin, mucus, and normal flora on and within the host.  
The second defense is the innate immune response which responds immediately, reacts 
non-specifically, and does not improve with exposure or remember invading pathogens (Tizard, 
2018). This is the natural immunity that a host would be born with. When a pathogen evades the 
primary physical barriers, innate immunity is triggered as an inflammatory reaction and takes 
only minutes to hours to be fully activated (Netea, Schlitzer, Placek, Joosten, and Schultze, 
2019). In the early stages of infection, the innate immune response is critical in limiting 
microbial spread and replication. However, if the invading pathogen has a high amount of 
virulence, the initial removal of this pathogen can fail. The final defense, the adaptive immune 
response, would then be activated to eliminate the pathogen which takes about one to two weeks 
(Netea et al., 2019). The adaptive immune response reacts slower and with more specificity, 
enhances upon re-exposure, has immunological memory for the invading pathogens, and takes 
time to develop (Tizard, 2018). This is important for secondary infections so as to respond more 
effectively and efficiently to restimulation and includes specialized immune cells such as B cells 
3 
and T cells (Netea et al., 2019). All three of these stages of defense are required to create a 
balanced immune response that is critical for host health. 
There are many aspects that play critical roles in the development of the innate immune 
response, including the nuclear factor-kappa B (NF-B). NF-B is a pathway of highly 
conserved transcription factors. This pathway regulates many important cellular behaviors, in 
particular, inflammatory responses, cellular growth, and apoptosis. Activation of various 
signaling pathways regulates the expression of both pro- and anti- inflammatory mediators to 
induce an inflammatory response (Lawrence, 2009). Receptors in these signaling pathways 
activates NF-B when foreign microbial products enter the host cell. However, when proteins 
are specifically targeted by microbes within the host cell, inflammation is impaired by inhibiting 
NF-B activation and expression of proinflammatory cytokines and chemokines (Lawrence, 
2009). The NF-B pathway is one of many mechanisms used in the innate immune response and 
serves as a general basis for the studies performed in this Master’s Thesis. 
 
Common Enteric Pathogens. Intestinal pathogens employ sophisticated strategies to 
colonize and infect many mammalian hosts worldwide. Most enteric infections are 
environmentally determined and typically enter the body through the oral route, which can occur 
through ingestion of contaminated food and water, by contact with animals and/or their 
environments, or by contact with an infected individual’s feces (Petri, Miller, Binder, Levine, 
Dillingham, and Guerrant, 2008). Many children are affected due to the constant desire to insert 
things into their mouths, and at this young age, absorption of key nutrients is critical. This leads 
to substantial effects on intestinal absorption, childhood development, nutrition, and global 
morbidity and mortality (Petri et al., 2008). Many of these effects are due to the pathogen’s 
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ability to cause persistent diarrhea and chronic, recurring enteric infections. Therefore, the study 
of the epidemiology, etiology, and pathophysiology of enteric infections is crucial. 
Among the leading causes of gastrointestinal tract infections are Gram-negative bacteria 
such as Escherichia coli and Salmonella. E. coli O157:H7 is the most common type of Shiga 
Toxin-producing E. coli (STEC). Although most strains are harmless and live in the intestines of 
healthy cattle, this strain is a major foodborne pathogen that causes severe disease around the 
world in humans (Lim, Yoon, and Hovde, 2010). Common sources of disease have been 
associated with eating undercooked, contaminated ground beef, ingesting produce items that 
have been contaminated through contact with cattle feces, or through drinking raw milk or water 
contaminated by fecal material of cattle. There are five categories of E. coli strains based on 
pathogenic mechanisms that cause different diseases due to acquiring different virulence genes 
(Donnenberg and Kaper, 1992). These categories are: enteroinvasive (EIEC), enteroaggregative 
(EAEC), enterotoxigenic (ETEC), enterohemorrhagic (EHEC), and enteropathogenic (EPEC). 
EPEC is one of the more common types out of these categories and is important to this study 
along with EHEC. 
Salmonella spp. are the second most common cause of diarrhea in the United States. The 
bacteria are commonly transferred through contaminated food or water either through animals or 
through a person, and occasionally through contact with animal or human feces (Aarestrup, 
Wiuff, Molbak, and Threlfall, 2003). Two types of Salmonella exist: 1) nontyphoidal, which is 
prevalent in the gastrointestinal tracts of many animals, and 2) typhoidal, where humans are the 
only known hosts, and it can cause enteric fever. Salmonella requires a certain set of genes 
encoded with Salmonella pathogenicity island 2 (SPI-2) to survive and replicate within host 
macrophages (Arpaia, Godec, Lau, Sivick, Mclaughlin, Jones et al. 2011). SPI-2 is involved in 
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intracellular bacterial replication and in initiation of systemic infections. SPI-2 also encodes a 
Type III Secretion System (T3SS) that aids in the translocation of SPI-2 effectors into the host 
cell and supports bacterial replication (Arpaia et al., 2011). This mechanism of infection by 
Salmonella forms one of the bases of this study. 
 
Types of Secretion Systems. Many mechanisms are utilized by bacterial pathogens when 
invading mammalian hosts and inhibiting the immune response. The secretion of bacterial 
proteins across the phospholipid membrane can promote bacterial virulence and is an essential 
component of these mechanisms (Green and Mecsas, 2016). The proteins that are secreted are 
termed “bacterial effectors” and are commonly transported into the cells of their hosts through a 
Type III Secretion System (T3SS), a Type IV Secretion System (T4SS), or a Type VI Secretion 
System (T6SS). The T3SS, T4SS, and T6SS are only a few of the bacterial protein secretion 
apparatuses, which are divided into various classes based on their specificity, arrangement, and 
function (Green and Mecsas, 2016). These protein secretion systems are vital to bacterial effector 
transport and bacterial growth inside the host cell. The secretion apparatus of focus for the 
concurrent experiments is the T3SS. 
T3SSs are found in a broad number of Gram-negative bacterial pathogens and symbionts. 
They act as injectosomes and “needle and syringe”-like apparatuses, due to their structure, to 
secrete effector proteins into the mammalian host cell (Green and Mecsas, 2016; Fig. 1). Protein 
substrates, such as NleB (E. coli and Citrobacter rodentium, a mucosal pathogen of mice that 
share several pathogenic mechanisms with E. coli) and SseK (Salmonella), are then secreted 
across both the inner and outer membranes of the bacterium. Anywhere from a few to several 
dozen of these effector proteins can be secreted depending on the pathogen that is involved 
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(Green and Mecsas, 2016). For a protein substrate to be recognized and secreted by the T3SS, a 
secretion signal is needed. These secretion signals are not cleaved during the process, are 
embedded within the N-termini of the substrate, and act as a “tag” that the T3SS recognizes and 
allows through for successful secretion (Green and Mecsas, 2016).  
The effector protein first goes through the base complex of the T3SS, then through the 
needle component, and lastly the translocon. The needle has a tip complex on the outer portion 
that is important in the regulation of effector secretion and sensing contact with host cells (Green 
and Mecsas, 2016). The tip also inserts the translocon into the cell membrane where it is 
assembled upon contact with the host cells. A pore is then formed that aids in effector delivery 
through host cell membranes; however, this pore is not important for the secretion of effectors 
outside of the bacterial pathogen (Green and Mecsas, 2016). Once inside the host cell, the 
functions of the effectors can vary among different pathogens. Yet, many effectors can establish 
an infectious niche either at mammalian tissue sites or within the cell by remodeling normal 
cellular functions (Green and Mecsas, 2016). 
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Figure 1 Gram-negative bacteria secretion systems. 
This figure was created using BioRender and followed Green and Mecsas (2016) 
depiction of the secretion systems. Gram-negative bacteria have the ability to transport 
proteins across phospholipid membranes using various protein secretion systems. 
Depending on the secretion system, proteins can secrete across one or multiple 
membranes. Some proteins utilize the T2SSs and T5SSs and are secreted in a two-step 
Sec- or Tat-dependent mechanism. This means that Sec or Tat secretion pathways can aid 
in the secretion of proteins across the inner membrane and from there, the proteins are 
transported across the outer membrane employing a second secretion system. Other 
proteins utilize the T3SSs, T4SSs, and T6SSs, where a one-step Sec- or Tat-independent 
process is used to transport their proteins across both bacterial membranes and an 
additional host cell membrane. All of the pathways are able to secrete proteins from the 
cytoplasm outside the cell. However, the secretion through the additional host cell 
membrane is specific to only T3SSs, T4SSs, and T6SSs, and delivers secreted proteins 
directly into the cytosol to inhibit certain host immune responses in the cell. 
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Bacterial Effectors and the Host Cell. Pathogenic bacteria are dependent on virulence 
proteins, or effectors, with enzyme activity to efficiently colonize and propagate within their 
hosts and counteract host innate immunity. NleB and SseK are two of the many bacterial 
effectors that are highly conserved in a Type III Secretion System (T3SS) and are the focus of 
the resulting studies (Gao, Wang, Pham, Feuerbacher, Lubos, Huang, et al., 2013). NleB is 
encoded by attaching and effacing pathogens (E. coli and Citrobacter rodentium), whereas SseK 
is encoded by Salmonella. Effectors reach the cytosol through either translocation across 
endosomal membranes or they are expressed and secreted directly into the host cell through 
bacterial secretory apparatuses (Boyer, Paquette, Silverman, and Stuart, 2011). Once in the cell, 
effectors modify host defense mechanisms and manipulate a variety of cellular processes, 
thereby inhibiting the innate immune system.  
Modulation of the innate immune system can be accomplished through E. coli T3SS 
effectors and can impact transcription factor NF-B, which regulates various host cell responses 
(Gao et al., 2013). NleB is one of many effectors that plays an important role in the virulence of 
E. coli by suppressing NF-B activation. NleB modifies mammalian glycolysis enzymes such as 
the FAS-Associated Death Domain protein (FADD), the Tumor Necrosis Factor (TNF) Receptor 
Type 1 (R1)-Associated Death Domain protein (TRADD), and the glyceraldehyde 3-phosphate 
dehydrogenase protein (GAPDH) by functioning as a translocated glycosyltransferase (Gao et 
al., 2013). When NleB is secreted across the T3SS into the host cell, the effector uses N-acetyl-
D-glucosamine (GlcNAc) to glycosylate target proteins on arginine residues. This then disrupts 
tumor necrosis factor receptor (TNFR)-associated factor (TRAF) signaling and effects 
downstream NF-B signaling (Qaidi, Scott, Hays, Geisbrecht, Watkins, and Hardwidge, 2020). 
The pro-inflammatory NF-B pathway is then inhibited which then blocks inflammation of the 
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innate immune system and catalyzes the addition of unusual post-translational modifications 
inside the host cell.  
This background information along with previous experimental results is what provoked 
further investigation in this research study. Two different approaches were created based on the 
prior knowledge of bacterial pathogens infecting the host cell through the use of bacterial 
effectors and the T3SS. These approaches included the 1) possible inhibition of NleB 
glycosylation or 2) inhibiting NleB itself, which would ultimately allow the host cell to continue 
with its immune response and eventual elimination of the pathogen. 
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Chapter 2 - NleB Glycosylation of Bacterial and Host Proteins 
Inside the Bacterium 
 2.1 Rationale for the study 
The focus of this study was on effectors NleB (E. coli and C. rodentium) and SseK (S. 
enterica). NleB was discovered to modify host protein substrates with N-acetyl glucosamine 
(GlcNAc) on arginine amino acid residues. This mechanism makes NleB an unusual 
glycosyltransferase since the guanidinium groups of arginine residues are poor nucleophiles 
(Gao et al., 2013; Qaidi et al., 2020). The normal functions of host target proteins that aid in the 
immune response are disrupted due to this post-translational modification. 
The activity of chaperones keeps effectors in a structural state that allows for successful 
secretion, whereas T3SS effectors are inactive within the bacterium until they are injected and 
fold into their active conformations (Gao et al., 2013; Qaidi et al., 2020). With previous findings 
of NleB glycosyltransferase activity targeting GAPDH function to inhibit the NF-B pathway 
(Gao et al., 2013), mass spectrometry was performed to identify various glycosylation substrates 
of NleB orthologs inside the bacterium. Qaidi et al. (2020) showed that glutathione synthetase 
(GshB) was glycosylated by NleB inside the bacterium on arginine residue R256. This served as 
the premise for the concurrent experiments with other glycosylation substrates MinC and FklB 
and with their arginine residues R107 and R129, respectively (Fig. 2). Another concurrent study 
focused on FADD, GAPDH, and TRADD and their arginine residues R117, R197/R200, and 
R235, respectively, for confirmation that human substrates can be glycosylated inside the 
bacterium. The purpose of this study was to see if effectors are active within the bacterium, 
which would go against previous studies that show effectors stay folded in their inactive 
conformations until secreted into the host cell, where they then fold into their active 
11 
conformations. If it is found that effectors are active inside the bacterium, then this would change 
previous thoughts and new areas of investigation on the extent to which other effectors with 
enzymatic activities that could be active within the bacterium may emerge. 
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Figure 2 Schematics of NleB Glycosylation of Bacterial and Host Substrates. 
This figure was created using BioRender. The E. coli effector, NleB, is secreted through 
the T3SS from the bacterium into the host cell to inhibit functions of host proteins. NleB 
acts as an unusual glycosyltransferase by using N-acetyl glucosamine (GlcNAc) to 
glycosylate the arginine residues of host substrates FADD on R117, GAPDH on 
R197/R200, and TRADD on R235. By doing this, NleB blocks the NF-B pathway and 
overall inhibits inflammation and the innate immune response. In previous studies, it was 
found that NleB may be able to act within the bacterium on bacterial proteins. These 
bacterial proteins were discovered by completing mass spectrometry experiments. NleB 
was found to glycosylate MinC on R107 and FklB on R129 within the bacterium, and our 
studies are aimed at proving this concept. 
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 2.2 Materials and Methods 
Strains and Molecular Cloning. The plasmids and strains used in this study are listed in 
Table 1 (Appendix A). WT nleB (Citrobacter rodentium) and its derivative DAD221-223/AAA 
were cloned into pET-42a. WT minC and its derivative minC R107A, and WT fklB and its 
derivative fklB R129A were cloned in pET-28a and pFLAG-CTC using restriction enzyme-based 
cloning. WT FADD, GAPDH, and TRADD and their derivatives FADD R117A, GAPDH 
R197A R200A, and TRADD R235A were cloned in pFLAG-CTC using ABC cloning (Qaidi 
and Hardwidge, 2019). 
 
Construction of Mutant Strains. All mutant strains of WT minC, fklB, FADD, GAPDH, 
and TRADD were made by completing a PCR with the WT plasmids and specific primers to 
switch the arginine amino acid residue to an alanine amino acid residue. The PCR plasmid was 
then purified, and restriction enzyme-based cloning was completed, where restriction sites are 
determined based on the plasmid, cloning PCR is completed, the insert and vector plasmid is 
digested, then ligated together and transformed in DH5- (NEB-) E. coli. 
 
Protein Expression and Purification. Proteins were expressed from E. coli BL21 (DE3) 
and induced with 0.5 mM IPTG when cultures reached an OD600 of 0.5. Cells were grown for an 
additional 4 h at 37 ºC and harvested using centrifugation. Cell pellets were resuspended in a 
1/40 culture volume of 50 mM Tris(hydroxymethyl)aminomethane hydrochloride (Tris-HCl) pH 
8.0 supplemented with 0.5 mg/mL lysozyme and protease inhibitor mixed solutions (Thermo 
Scientific). Bacterial suspensions were incubated on ice for 30 min with occasional shaking. An 
equal volume of 50 mM Tris-HCl pH 8.0, 2 M NaCl, 8 mM imidazole, 20 % glycerol, and 1 % 
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Triton X-100 was added to the mix and an additional incubation on ice for 30 min with 
occasional shaking. Cell lysates were sonicated on ice and then centrifuged. Two mL Ni-NTA 
slurry (Qiagen) was added to the supernatant of the sonicated lysate and was gently rotated for 1 
h at 4 ºC. The mixture was loaded on a Poly-Prep Chromatography Column (BioRad) and 
washed in 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 60 mM imidazole, and 10 % glycerol. 
Proteins were eluted in 50 mM Tris-HCl pH 8.0, 600 mM NaCl, 250 mM imidazole, and 10 % 
glycerol. 
 
Bacterial Strains and Growth Conditions. MinC and FklB, and MinC(R107A) and 
FklB(R129A), respectively, were electroporated with WT and mutant C. rodentium, S. enterica, 
enteropathogenic E. coli (EPEC), or enterohemorrhagic E. coli (EHEC). FADD, GAPDH, and 
TRADD, and FADD(R117A), GAPDH(R197A/R200A), and TRADD(R235A), respectively, 
were electroporated with WT and mutant C. rodentium. Two colonies from each strain were 
grown in LB medium with either carbenicillin (Cb 100; 100 g/mL) (MinC, FklB, and FADD) 
or kanamycin (Kan 50; 50 g/mL) (GAPDH and TRADD) and 0.5 mM IPTG to induce growth. 
Cultures were incubated overnight at 37 ºC while shaking.  
 
Glycosylation Assays. In vitro glycosylation assays were performed as described 
previously (El Qaidi et al, 2017) using 200 nM of NleB1 or its orthologs with 1M of either WT 
MinC or MinC R107A, or WT FklB or FklB R129A in 50 mM Tris-HCl pH 7.4, 1 mM UDP-
GlcNAc, 10 mM MnCl2, and 1 mM DTT. After 1.5 h incubation at room temperature, samples 
were subjected to western blotting using either an anti-HisTag monoclonal antibody (Abcam, 
Cambridge, UK) or anti-FlagTag monoclonal antibody (Abcam, Cambridge, UK) to detect 
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protein HisTag or FlagTag expression and an anti-R-GlcNAc monoclonal antibody (Abcam) to 
detect NleB glycosylation of proteins. In vivo glycosylation assays for bacterial proteins were 
performed using C. rodentium and S. enterica strains electroporated with plasmids expressing 
FLAG-His-MinC or FLAG-His-MinC(R107A), or FLAG-His-FklB or FLAG-His-FklB(R129A). 
In vivo glycosylation assays for host proteins were performed using the strain C. rodentium 
electroporated with plasmids expressing FLAG-His-FADD or FLAG-His-FADD(R117A), 
FLAG-His-GAPDH or FLAG-His-GAPDH(R197A R200A), or FLAG-His-TRADD or FLAG-
His-TRADD(R235A). Transformed bacteria were grown overnight in the presence of 0.5 mM 
IPTG and harvested using centrifugation. His-tagged proteins were purified as described above 
and then subjected to western blotting using an anti-HisTag monoclonal antibody (Abcam, 
Cambridge, UK) and an anti-R-GlcNAc monoclonal antibody (Abcam, Cambridge, UK).  
 
SDS-PAGE and Western Blot Analysis. WT MinC and MinC R107A, WT FklB and 
FklB R129A, WT FADD and FADD R117A, WT GAPDH and GAPDH R197A R200A, and 
WT TRADD and TRADD R235A cells for western blot analysis were harvested by 
centrifugation and suspended in 1 x sample SDS-loading dye (60 mM Tris-HCl pH 6.8, 1 % 
SDS, 1 % -mercaptoethanol, 20 % glycerol, 0.01 % bromophenol blue). Cell extracts were then 
brought to a boil by sonication and heated at 98 ºC for 5 min, then centrifuged briefly. Cell 
samples were loaded onto a 15 % SDS-PAGE polyacrylamide gel and were ran using a mini-
protean tetra system (Bio-Rad, Hercules, CA) at 25 mAmp per gel for 1.5 h. For SDS-PAGE 
assays, gels were then stained for 30 min while shaking with Coomassie brilliant blue and then 
distained as necessary. For western blot analysis, polyacrylamide gels were ran then transferred 
to a nitrocellulose filter membrane by following the semi-dry transfer unit (Hoefer Semi Phor) 
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and running at 100 V for 1 h using a mini-protean tetra system (Bio-Rad, Hercules, CA). After 
running the transfer, the first monoclonal antibody (anti-HisTag Mouse or anti-FlagTag mouse 
and anti-R-GlcNAc Rabbit) was added with a 1/5,000 dilution and either incubated overnight at 
4 ºC shaking or incubated for 1 h at room temperature. The membrane was washed 3 x 10 
minutes with Phosphate-Buffered Saline/Tween (PBST) and after, the second monoclonal 
antibody was added (goat anti-mouse and goat anti-rabbit) with a 1/5,000 dilution and incubated 
shaking at room temperature for 1 h. The membrane was then washed 3 x 10 minutes with PBST 
and detected using an Odyssey FC Imager (LI-COR, Lincoln, NE). 
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 2.3 Results 
MinC and FklB are glycosylated in vitro but are not glycosylated at endogenous 
levels of NleB. Mass spectrometry experiments were performed and used to identify new 
glycosylation substrates of NleB orthologs from EHEC strains. This was done by using EHEC 
strains that expressed NleB1 to infect HEK293T cells (Qaidi et al., 2020). To validate the mass 
spectrometry data, we conducted in vitro glycosylation experiments. MinC, the septum site-
determining E. coli protein used in cell division, and FklB, the peptidyl-prolyl cis-trans 
isomerase E. coli protein that promotes bacterial stress tolerance and virulence, were first cloned 
in pET-28a for in vitro studies and pFLAG-CTC for further in vivo studies. The arginine to 
alanine mutants were also cloned in these plasmids to observe variation between the parent and 
mutant strains. Protein expression of MinC and FklB in pET-28a was detected using SDS-PAGE 
analysis (Fig. 3A).  
C. rodentium NleB was used based off of the findings in Qaidi et al. (2020) with either 
MinC or FklB to investigate glycosylation within these proteins. In vitro glycosylation assays 
following protocols from El Qaidi et al. (2017) were conducted using the anti-HisTag and anti-
R-GlcNAc monoclonal antibodies and by expressing recombinant forms of wild-type (WT) 
MinC and FklB or MinC(R107A) and FklB(R129A), respectively. NleB glycosylated the WT 
MinC and WT FklB, which was consistent with the mass spectrometry assays. However, the 
MinC(R107A) and FklB(R129A) mutants were also glycosylated by NleB (Fig. 3B). Within 
these assays, FADD was used as a positive control as a known NleB substrate (Qaidi et al. 2020). 
C. rodentium NleB was used to confirm that NleB was active in the bacterium. The C. rodentium 
18 
NleB DAD221-223/AAA mutant was used as a negative control due to its lack of glycosylation 
activity. 
We then generated a minC and fklB deletion in C. rodentium and complemented these 
strains with the cloned FLAG-tagged versions of either WT MinC or MinC(R107A), or WT 
FklB or FklB(R129A) for in vivo analysis. MinC, FklB and the arginine to alanine mutants were 
all expressed as inferred from SDS-PAGE and western blotting using an anti-FlagTag 
monoclonal antibody (Fig. 3C). However, using the anti-R-GlcNAc monoclonal antibody for 
detection established that these proteins were not glycosylated by NleB. We conducted similar 
analyses with S. enterica, EHEC, and EPEC, and similarly MinC or FklB were not glycosylated 
(Fig. 3D). For these assays, a gshB deletion in C. rodentium with a FLAG-tagged version of WT 
GshB was utilized as a positive control, while the gshB deletion in C. rodentium with FLAG-
tagged GshB(R256A) was used as the negative control, both as confirmed NleB substrates in 
Qaidi et al. (2020). 
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Figure 3 NleB glycosylates MinC R107 and FklB R129 in vitro, but not at 
endogenous levels of NleB. 
 (A) Coomassie blue staining and protein purification to detect expression of WT and 
point mutations MinC and FklB cloned in pET-28a. (B) MinC and FklB are glycosylated 
by NleB on their arginine residues in vitro. Point mutations from arginine to alanine was 
completed on arginine residues R107 and R129 and were also glycosylated by NleB in 
vitro. Anti-HisTag and anti-R-GlcNAc monoclonal antibodies were used for western 
blotting. (C) Coomassie blue staining after electroporation in C. rodentium, S. enterica, 
EPEC, and EHEC with WT and point mutations MinC and FklB in pFLAG-CTC protein 
expression was detected. (D) WT and point mutants MinC and FklB show FlagTag 
expression, but are not glycosylated by NleB within C. rodentium, S. enterica, EPEC, or 
EHEC. Anti-FlagTag and anti-R-GlcNAc monoclonal antibodies were used for western 
blotting. WT GshB in C. rodentium is the positive control (yellow). 
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NleB glycosylation verification through host proteins. Previous work has shown that 
NleB glycosylates mammalian substrates FADD, GAPDH, and TRADD inside the host cell 
(Park, Kim, Yoo et al et al., 2018). From this information, we attempted to determine whether 
these proteins could be glycosylated within the bacterium. We expressed FLAG-tagged versions 
of either WT FADD or FADD(R117A), WT GAPDH or GAPDH(R197A/R200A), or WT 
TRADD or TRADD(R235A) in WT C. rodentium and mutant C. rodentium NleB DAD221-
223/AAA and then confirmed protein expression through SDS-PAGE analysis (Fig. 4A). Protein 
expression was also confirmed through western blotting using an anti-HisTag monoclonal 
antibody. WT FADD, WT GAPDH, and WT TRADD were glycosylated by endogenous levels 
of NleB, detected using an anti-R-GlcNAc monoclonal antibody (Fig. 4B). Furthermore, 
mutating the relevant substrate arginine was found to be sufficient to eliminate in vivo 
glycosylation (Fig. 4C). For this set of assays, the gshB deletion in C. rodentium with a FLAG 
tagged version of WT GshB was utilized again as the positive control while the gshB deletion in 
C. rodentium with FLAG tagged GshB(R256A) served as the negative control. Both were 
confirmed NleB substrates in Qaidi et al. (2020). Thus, mammalian substrates of NleB are 
glycosylated within C. rodentium, reinforcing the notion that NleB is active within the 
bacterium.  
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Figure 4 Mammalian substrates of NleB are glycosylated within C. rodentium. 
 (A) Coomassie blue staining after electroporation in WT C. rodentium and mutant, C. 
rodentium NleB DAD221-223/AAA with host proteins WT FADD, GAPDH, and TRADD 
and their point mutants FADD(R117A), GAPDH(R197A/R200A), and TRADD(R235A), 
respectively, are expressed. (B) WT FADD, GAPDH, and TRADD are all glycosylated at 
endogenous levels of NleB within C. rodentium, and HisTag expression is detected for all 
proteins. Mutating the relevant substrate arginine is sufficient to eliminate in vivo 
glycosylation. Anti-HisTag and anti-R-GlcNAc monoclonal antibodies were used for 
western blotting. WT GshB within C. rodentium is glycosylated by NleB and is shown as 
the positive control (yellow) while GshB(R256A) is shown as a negative control (red). 
(C) Host proteins FADD, GAPDH, and TRADD are not glycosylated by NleB in mutant 
C. rodentium NleB DAD221-223/AAA, as hypothesized. Again, WT GshB is shown as the 
positive control (yellow) and GshB(R256A) is shown as the negative control (red). 
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 2.4 Discussion 
NleB inhibits host pro-inflammatory immune responses mediated by NF-B by 
glycosylating host regulatory proteins on arginine residues (Park et al., 2018). In recent studies 
completed by Qaidi et al. (2020), the bacterial protein GshB was also found to be glycosylated 
by NleB inside the bacterium on arginine residue R256. From this information, we decided to 
analyze two other bacterial proteins also found through mass spectrometry that were 
glycosylated by NleB on their arginine residues. In our assays, we found that the WT MinC and 
WT FklB were glycosylated by NleB, suggesting that they may be glycosylated within the 
bacterium and that in vivo assays were needed. However, when point mutations were used to 
change the relevant arginine residues to alanines, we still saw that glycosylation by NleB was 
possible (Fig. 3B). This was not expected as there was only one glycosylated arginine residue 
found in the mass spectrometry experiments, and so, this suggests that there may have been 
another arginine residue in the amino acid sequence that was being targeted by NleB. This can be 
confirmed by either creating a mutant library and mutating all the arginine residues to an alanine 
within the signal sequence or by performing another mass spectrometry experiment on MinC and 
FklB to see if there are other arginine hits that are identified during the experiment. 
We then conducted in vivo studies on MinC and FklB, and their arginine to alanine point 
mutations, MinC(R107A) and FklB(R129A), respectively. The bacterial proteins were 
introduced into WT C. rodentium and western blot analysis was completed. Protein HisTag 
expression was detected for all proteins, WT MinC, WT FklB, MinC(R107A), and FklB(R129A) 
but NleB glycosylation was not seen for any of the proteins. We hypothesized that there may be 
a different bacteria that glycosylation would be more successful in. We introduced the same 
proteins into WT S. enterica, WT EPEC, and WT EHEC and western blotting was performed. 
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Protein HisTag expression was again detected. However, NleB glycosylation was not detected 
for any of the proteins (Fig. 4B). This strongly suggests that MinC and FklB are not glycosylated 
at the endogenous level of NleB and that these bacterial proteins may not be actual targets of 
NleB. 
NleB/SseK activities in the host cell modifies host proteins involved in the innate 
immune response, such as FADD, GAPDH, and TRADD. We wanted to confirm whether these 
proteins could be glycosylated inside the bacterium. The host proteins FADD, GAPDH, and 
TRADD, and the mutated forms of the same proteins [FADD(R117A), 
GAPDH(R197A/R200A), and TRADD(R235A), respectively], were introduced into WT C. 
rodentium and western blotting was completed. Protein HisTag expression was detected for all 
host proteins. NleB glycosylation was observed for WT FADD, WT GAPDH, and WT TRADD, 
but not for their point mutated forms as hypothesized. We also observed that WT FADD had a 
much stronger glycosylation signal than WT GAPDH or WT TRADD, suggesting that FADD is 
a better NleB glycosylation substrate compared to GAPDH or TRADD. We confirmed that the 
results that we received were not experimental error through the use of our positive control, WT 
GshB in WT C. rodentium, and our negative control, GshB(R256A) in WT C. rodentium. No 
other experiments besides the previous GshB study by Qaidi et al. (2020) have seen these results, 
which makes this and the previous study the first evidence of activity within the bacterium. In 
summary, the bacterial proteins MinC and FklB are not glycosylated to endogenous levels of 
NleB, and this was confirmed through the in vivo NleB glycosylation of host proteins FADD, 
GAPDH, and TRADD inside the bacterium.   
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Chapter 3 - Secretion of Effector 1-20 Amino Acid Nanobody 
Fusions 
 3.1 Rationale for the Study 
Collaboration with Dr. Luis Angel Fernandez on the utilization of nanobodies, and an 
earlier study by Charpentier et al. (2004) provoked the second study completed in this thesis. 
Nanobodies are derived from camelid single chain antibodies and are small recombinant binders 
that can bind to antigens similarly to antibodies (Brunner and Schenck, 2020). They have simple 
structures which make them fairly easy to work with in the laboratory setting and enables 
recombinant expression and simplistic cloning. They also act as blockers or modifiers of protein 
activity, hence their importance in the following experiments. In a previous article, a 1-20 amino 
acid (AA) signal sequence from an effector protein that would normally be secreted through a 
Type III Secretion System (T3SS) was fused upstream from TEM-1 -lactamase, a protein that 
would not normally be secreted (Charpentier and Oswald, 2004). The effector 20 AA signal 
sequences that were used in this instance were derived from the Cif, Tir, Map, and EspF 
effectors. Successful secretion and translocation of the TEM-1 -lactamase fused with the 
effector 20 AA signal sequence in a type III-dependent but chaperone-independent manner was 
observed (Charpentier and Oswald, 2004). Once secreted, the protein fused with the 20 AA 
signal sequence was able to block the G2/M phase transition.  
The study for this thesis followed similar protocols to identify if a camelid nanobody that 
would not normally be secreted through a functional T3SS could be secreted if fused to a T3SS 
secretion signal. Certain effectors could be modular proteins composed of an exchangeable N-
terminal secretion and translocation signal (STS) and can be linked to a C-terminal effector 
domain. In this case, if a 20 AA signal sequence from an effector that is secreted is fused to the 
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nanobody and an attenuated bacterium with an engineered T3SS is created, then successful 
secretion may be seen. The attenuated bacterium is needed because it would be free of any toxins 
a normal bacterium may have, making it safe, and the T3SS would function as a normal T3SS. 
The 20 AA signal sequence would act as a tag specific to T3SSs so that the nanobody fusion 
could be injected through the T3SS into the host cell. The 20 AA signal sequence nanobody 
fusion would then be able to block NleB from targeting host proteins and stop NleB from 
inhibiting the host immune response. This served as the premise for the concurrent experiments 
with the therapeutic nanobody fusions and is further explained in Fig. 5.
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Figure 5 Schematics of the Secretion of 20 AA Signal Sequence Nanobody Fusions. 
This figure was created using BioRender. The E. coli effector, NleB, is secreted through 
the T3SS from the bacterium into the host cell to inhibit functions of host proteins. NleB 
acts as an unusual glycosyltransferase by using N-acetyl glucosamine (GlcNAc) to 
glycosylate the arginine residues of host substrates by blocking the NF-B pathway and 
overall inhibiting inflammation and the innate immune response. From a previous study, 
the idea was brought about that fusing a signal sequence from effectors that would 
normally be secreted through T3SSs to a substrate not normally secreted, then the signal 
sequence would promote secretion through a T3SS. For this study, an attenuated 
bacterium with an engineered T3SS that functions as a normal T3SS would be needed. A 
20 AA signal sequence from certain effectors that were found to be secreted through 
T3SSs would then be fused to the nanobodies. Once secreted, the nanobody fusion could 
then act as a therapeutic to inhibit NleB from glycosylating target proteins and allow the 
host immune system to respond to the invading pathogen. 
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 3.2 Materials and Methods 
Construction of the 20 Amino Acid Signal Sequence Nanobody Fusion. Specific 
primers were constructed to create a plasmid that contained the camelid nanobody and the 20 AA 
signal sequence from a variety of effectors. The 20 AA signal sequence was added upstream 
towards the N-terminus of the nanobody sequence. T3SS signal sequences were derived from 
effectors EspF, Tir, NleB2, NleC, NleD, NleF, and NleH1. PCR was completed with nanobodies 
produced by Dr. Ramon Hurtado-Guerrero (Ruano-Gallego D, Álvarez B, and Fernández LÁ 
(2015) and specific primers to add on the 20 AA signal sequence from the effectors. Expression 
plasmids were created using ABC cloning (Qaidi et al, 2019) and are listed in Table 2 (Appendix 
B).  
 
Bacterial Strains and Growth Conditions. Nanobodies fused with effector 1-20 AA 
signal sequence plasmids were electroporated with either the strain sent from Dr. Ramon 
Hurtado-Guerrero Synthetic Injector E. coli (SIEC) and its mutant SIEC P1 for one experiment, 
or WT and mutant C. rodentium for the other experiment. Two colonies from each strain were 
grown in either DMEM or LB broth with carbenicillin (Cb 100; 100 g/mL) and 0.5 mM IPTG 
to induce growth. Cultures were incubated overnight at 37 ºC while shaking. Experiments were 
done with both DMEM and LB broth to help visualize if there was a significant difference in 
growth between the two.  
 
Acetone Precipitation. Overnight cultures made from the 1-20 AA signal sequence 
nanobody fusions and electroporated with either SIEC and SIEC P1 or WT and Mutant C. 
rodentium were centrifuged at 4 ºC for 10 min. The culture supernatant (15 mL) was obtained 
28 
and filtered with a 25 mL luer-slip plastic syringe through a 0.20 m sterile syringe filter 
(Corning, Inc., Corning, NY) into a 50 mL tube and the pellet was stored for later use at -20 ºC. 
Trichloroacetic acid (TCA) (5 %) was added to the filtered supernatant, mixed, and either 
precipitated on ice for 1 h or precipitated overnight at 4 ºC. The mix was then centrifuged for 30 
min at 4 ºC and the maximum amount of supernatant was discarded by slowly inverting the tube. 
The pellet was washed 2 x in 5 mL of ice-cold acetone while scraping the sides of the tubes. 
After the last wash, the pellet was resuspended in 0.5 to 1 mL of ice-cold acetone and 
centrifuged at 4 ºC for 10 min. The maximum amount of supernatant was discarded by slowly 
inverting the tube and the pellet was resuspended in 20 L of phosphate buffered saline (PBS) 
and 20 L of 5 x sample SDS-loading dye (60 mM Tris-HCl pH 6.8, 1 % SDS, 1 % -
mercaptoethanol, 20 % glycerol, 0.01 % bromophenol blue).  
 
Analysis of Expression and Secretion of Nanobody Fusion Proteins. A portion of the 
pellet was retrieved for sampling to visualize before and after the acetone precipitation, and 50 
L of 1 x SDS-loading dye was added. The pellet and precipitated supernatant cell extracts were 
brought to a boil through sonication and heated at 98 ºC for 5 min, then centrifuged briefly. Cell 
samples were electrophoresed on a 15 % SDS-PAGE polyacrylamide gel and were ran using a 
mini-protean tetra system (Bio-Rad, Hercules, CA) at 25 mAmp per gel for 1.5 h. For SDS-
PAGE assays, gels were then stained for 30 min while shaking with Coomassie brilliant and then 
distained for 30 minutes while shaking. For western blot analysis, polyacrylamide gels were ran 
then transferred to a nitrocellulose filter membrane by following the semi-dry transfer unit 
(Hoefer Semi Phor) and running at 100 V for 1 h using a mini-protean tetra system (Bio-Rad, 
Hercules, CA). After running the transfer, anti-HisTag mouse monoclonal antibody was added 
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with a 1/5,000 dilution and either incubated overnight at 4 ºC shaking or incubated for 1 h at 
room temperature. The membrane was washed 3 x 10 minutes with Phosphate-Buffered 
Saline/Tween (PBST) and after, the second monoclonal antibody was added (goat anti-mouse) 
with a 1/5,000 dilution and incubated shaking at room temperature for 1 h. The membrane was 
then washed 3 x 10 minutes with PBST and detected using an Odyssey FC Imager (LI-COR, 
Lincoln, NE). 
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 3.3 Results 
Nanobodies with effector signal sequences are possible mediators of translocation. 
The nanobody is a single-domain antibody found in camelids and sharks that has the ability to 
bind to antigens just as an antibody would do, making them small, easy to obtain, and ideal for 
research. We used five nanobodies in the study that were produced and sent from Dr. Ramon 
Hurtado-Guerrero for this reason. Each nanobody started with “CAG” at the beginning of each 
sequence; “DYGS” is a recognition sequence for detection with an antibody that was also added 
into the nanobody sequences. To test the nanobodies as reporters for type III translocation, we 
fused each of the five nanobodies to the C-terminus of EspF1-20 AA signal sequence, since EspF 
possesses an N-terminal STS, using PCR and specific primers. A 20 AA signal sequence was 
utilized because it was found in the studies of Charpentier and Oswald (2004) that a 20 AA 
sequence was optimal for successful secretion and translocation. After we completed the fusion, 
the EspF1-20Nbs were cloned into pFLAG-CTC. Nanobody expression plasmids were 
electroporated into WT C. rodentium NleB, grown overnight, and then bacterial supernatants 
were acetone precipitated to concentrate the low concentration of the protein into a new pellet, 
and then the abundance of proteins in the supernatant was analyzed. We then completed SDS-
PAGE analysis and western blotting. We detected the expression of all protein in the pellet, but 
the proteins in the supernatant were either very low in abundance or not detected at all (Figs. 6A-
B). 
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Figure 6 Expression of nanobody fusions is only detected within C. rodentium before 
precipitation. 
 (A) The effector EspF 20 AA signal sequence was fused to five nanobodies and were 
chosen to complete this study. Coomassie blue staining was completed and all EspF1-
20NB fusions were electroporated in WT C. rodentium and acetone precipitated to 
concentrate the low concentration of the protein into a new pellet. Then the abundance of 
proteins in the supernatant was analyzed. Expression was seen before precipitation for 
NBs 1, 2, 5, and 14, but low expression concentrations were seen after precipitation. NB 
13 was not expressed. (B) EspF1-20NB fusions were detected before precipitation, but not 
after precipitation. Nanobody fusions were not secreted through the T3SS within C. 
rodentium. An anti-HisTag monoclonal antibody was utilized for western blotting. 
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The first 20 codons of effectors do not mediate secretion of nanobodies. Once 
expression of the EspF1-20Nb in combination with WT C. rodentium but no secretion was 
observed, we decided to take one nanobody from the samples and complete further testing with 
various effectors that would also possess an N-terminal STS. We identified other STS in the first 
20 codons of EPEC and EHEC effectors, then constructed fusions of the nanobody to the first 20 
AA residues. The effectors identified and utilized were Tir (previously shown to have successful 
secretion in Charpentier and Oswald (2004)), NleB2, NleC, NleD, NleF, and NleH1. We also 
used the effector EspF again for verification and reproducibility. We then cloned them in 
pFLAG-CTC for in vivo preparation as in the first part of this study with EspF. Wanting to use a 
different Gram-negative bacteria to see if other bacteria may promote secretion more effectively, 
all nanobodies were electroporated into WT Synthetic Injector E. coli (SIEC) and its mutant, 
SIEC P1, strains. We grew the bacteria overnight and bacterial supernatants were acetone 
precipitated to concentrate the low concentration of the protein into a new pellet, and then the 
abundance of proteins in the supernatant was analyzed. Nanobody fusions were expressed in the 
WT SIEC and mutant SIEC P1 strains, but they were not secreted, as inferred from SDS-PAGE 
(Fig. 7A) and western blotting (Fig. 7B).  
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Figure 7 Some effector signal sequences work more efficiently than others, and 
nanobody fusions are expressed within E. coli but are not secreted. 
 (A) Nanobody 2 was used for the rest of the experiments since expression of the protein 
was found to be more abundant than the other nanobodies. Nanobody 2 was fused to 
signal sequences from effectors EspF, NleB2, NleC, NleD, NleF, NleH1, and Tir. 
Nanobody fusions were electroporated in WT SIEC and mutant SIEC P1 and acetone 
precipitated to concentrate the low concentration of the protein into a new pellet. 
Coomassie blue staining was completed and expression was seen before precipitation for 
all proteins except NleC1-20NB, but low concentrations of expression was detected after 
precipitation (B) EspF1-20NB, NleD1-20NB, NleF1-20NB, and Tir1-20NB fusion expressions 
were detected before precipitation, but no protein concentration was detected after 
precipitation. Anti-HisTag monoclonal antibody was utilized for western blotting. 
Nanobody fusions were not secreted through the T3SS within SIEC or SIEC P1. 
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We then tested WT C. rodentium and mutant C. rodentium NleB DAD221-223/AAA with 
three of the nanobody fusions. The nanobody fusions EspF1-20Nb, NleF1-20Nb, and Tir1-20Nb 
were chosen because they were expressed in greater abundance than the other fusions. The same 
protocol that was completed for SIEC and SIEC P1 was followed, and similar findings from the 
SIEC and SIEC P1 tests were found. Expression of all proteins in the pellet fraction were 
detected, but the proteins in the supernatant fraction after acetone precipitation were either very 
low in abundance or not detected at all. This suggests that there is no nanobody secretion through 
the T3SS (Figs. 8A-C). 
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Figure 8 A 20 AA signal sequence does not promote secretion, and nanobody fusions 
are not secreted through the T3SS. 
Coomassie blue staining, western blotting, and electroporation with WT C. rodentium and 
mutant C. rodentium NleB DAD221-223/AAA was completed on the three nanobody 
fusions that had a higher abundance of protein throughout the study, (A) EspF1-20NB, (B) 
NleF1-20NB, (C) Tir1-20NB. Nanobody fusions were acetone precipitated to concentrate 
the low concentration of protein. Expression before precipitation was detected through 
SDS-PAGE analysis and western blotting, but low to no concentration of protein was 
detected after precipitation. An anti-HisTag monoclonal antibody was utilized for 
detection in western blotting. Nanobody fusions were not secreted through the T3SS 
within WT or mutant C. rodentium, and the 20 AA signal sequence does not promote 
secretion of nanobody fusions through the T3SS. 
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 3.4 Discussion 
In a past experiment by Charpentier and Oswald (2004), the LEE-encoded effectors Tir 
and EspF had been studied to determine the domains utilized for translocation across a T3SS, 
and the signal sequences of both were confirmed to promote translocation and secretion of TEM-
1 -lactamase through a T3SS. EspF and Tir were also confirmed to contain an STS in their N 
termini, suggesting that LEE-encoded and non-LEE-encoded effectors could use the same 
molecular mechanisms to move from a bacterial cell to a host cell through a T3SS. In our study, 
we took a 20 AA signal sequence from EspF, Tir, NleB2, NleC, NleD, NleF, and NleH1 to 
create recombinant fusions of these T3SS signals to nanobodies. This would then determine if 
T3SS-dependent nanobody secretion would be promoted. Our decision to take the 20 AA signal 
sequence came from the Charpentier and Oswald (2004) study that revealed the first 16 N-
terminal amino acid residues of an effector were sufficient for the secretion and delivery of 
protein into the host cell by WT EPEC strains. The first 20 N-terminal amino acid residues of 
each effector that marked proteins for secretion through their signals were fused to the 
nanobodies to examine if secretion of the nanobody through a T3SS was promoted. We 
hypothesized that, once inside the host cell, the nanobody fusions had the possibility to be 
utilized as a therapeutic method to inhibit NleB inside the cell so that an immune response 
against the pathogen would be encouraged. 
Our first tests were completed with EspF1-20Nb fusion in WT C. rodentium and the 
mutant C. rodentium strains. When the EspF1-20 signal sequence was first observed in 
combination with the five different nanobodies, secretion through the T3SS was not seen, and 
suggested that a different effector signal sequence may be needed for delivery of the nanobody 
through the T3SS and that a different strain of E. coli may work better than C. rodentium. We 
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tested Tir1-20Nb, NleB21-20Nb, NleC1-20Nb, NleD1-20Nb, NleF1-20Nb, and NleH11-20Nb fusions in 
WT Synthetic Injector E. coli (SIEC) and its mutant, SIEC P1. No secretion through the T3SS of 
the nanobody fusions was observed. Lastly, to confirm that secretion of the nanobody fusions 
was not possible, EspF1-20Nb, NleF1-20Nb, and Tir1-20Nb in WT C. rodentium and mutant C. 
rodentium NleB DAD221-223/AAA was tested. Nanobody secretion was not observed, suggesting 
that a different method may be more apt for successful secretion into the host cell. It was also 
suggested to use an NleB deletion mutant instead of the inactive C. rodentium, which should be 
performed in future studies. Since we did not observe secretion of the nanobody fusions at any 
point, we did not examine translocation of the nanobodies. This suggestion is made since several 
other methods have been reported before to monitor the secretion and translocation through the 
T3SS of other proteins. It can also be proposed that somewhere in the acetone precipitation 
assay, part or all of the protein is not being fully precipitated, and more of the precipitated 
sample needs to be examined through western blot and SDS-PAGE analysis, since only 13 L of 
each nanobody fusion was examined out of a total of 40 L.  
The studies of Charpentier and Oswald (2004) found that the full-length effector-protein 
fusion secreted and translocated through the T3SS more efficiently than the effector 16 AA 
signal sequence fused to the protein. These studies show that the N-terminal signal mediates 
secretion and translocation with a lower efficiency than the full length effectors, and suggests 
that in the case of our studies, using the full length of the effector signal sequence fused to the 
nanobodies would have been worth examining and should be examined in the future. 
Furthermore, the question remains if nanobodies are in fact efficient to be delivered through a 
T3SS or if another protein should be chosen to fuse the effector signal sequences to. Our positive 
controls were supposed to be the EspF and Tir 20 AA signal sequences since they had promoted 
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successful secretion in the Charpentier and Oswald (2004) study. However, the effectors fused to 
the nanobodies did not promote secretion for the nanobodies. In the future, it would be essential 
to include the EspF and Tir AA signal sequences fused to TEM-1 -lactamase, as proven to be 
secreted in the previous study, as a positive control for future studies and should have been 
included in this thesis’ studies. 
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Chapter 4 - Conclusion and Future Studies 
Escherichia coli and Salmonella enterica are still among the leading causes of 
gastrointestinal tract infections. Over 200 million cases of gastroenteritis per year are reported in 
the United States alone, with children, the immunocompromised, and the elderly most affected. 
E. coli and S. enterica interact with their mammalian hosts by secreting effectors, such as NleB 
and SseK, through a type III secretion apparatus into the host cells. There, they target host 
proteins to inhibit host protein function that is involved in the innate immune response, which in 
turn impairs inflammation through blocking NF-B activation.  
The first part of these studies focused on NleB and SseK acting as unusual 
glycosyltransferases that glycosylate host protein substrates on arginine residues with N-acetyl 
glucosamine (GlcNAc) to block the function of host proteins. These effectors were initially 
thought to be inactive within the bacterium, however, were later found through mass 
spectrometry experiments to glycosylate substrates inside the bacterium. One of these identified 
substrates, GshB, was confirmed to be glycosylated on arginine residue R256 by Qaidi et al. 
(2020). Another two bacterial proteins, MinC and FklB glycosylated on arginine residues R107 
and R129, respectively, were also postulated to be glycosylated by NleB. Two main conclusions 
were drawn from these experiments. One was that MinC and FklB were glycosylated in vitro on 
their arginine residues but were also found to be glycosylated on their arginine to alanine point 
mutants, which was not hypothesized as there was only one glycosylated arginine residue 
originally reported. The second was that even though in vitro analyses presented glycosylation of 
MinC and FklB on their arginine residues, these bacterial substrates were not found to be 
glycosylated at endogenous levels of NleB. This study was then verified through successful 
glycosylation of host proteins FADD, GAPDH, and TRADD on arginine residues R117, 
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R197/R200, and R235, respectively, by endogenous levels of NleB. As hypothesized, mutating 
the relevant substrate arginine was sufficient to eliminate in vivo glycosylation. These results 
concluded that mammalian substrates of NleB are glycosylated within C. rodentium, which 
reinforced the idea that NleB is active within the bacterium. 
The second part of these studies focused on the secretion of a nanobody fused to a 20 AA 
signal sequence from effectors that would normally be secreted through a T3SS. Once secreted, 
the nanobody fusion could then act as a therapeutic to inhibit NleB from glycosylating target 
proteins and allow the host immune system to respond to the invading pathogen. In our first 
experiment, we tested the protein concentrations of EspF1-20Nb fusions in WT C. rodentium 
NleB before and after acetone precipitation. Our results revealed that there was no successful 
secretion through the T3SS. The next experiment was based on trying to find an effector that 
may aid in nanobody secretion more effectively and using a different Gram-negative bacterium 
to see if secretion was possible. Tir1-20Nb, NleB21-20Nb, NleC1-20Nb, NleD1-20Nb, NleF1-20Nb, 
and NleH11-20Nb fusions were tested in WT Synthetic Injector E. coli (SIEC) and its mutant, 
SIEC P1, and protein concentrations in the pellet and after precipitation was measured. Yet 
again, no successful secretion through the T3SS was seen. Our last experiment was completed to 
confirm that the nanobody fusions were not secreted by Gram-negative bacteria. Three nanobody 
fusions were chosen as a result of their expression being in greater abundance than the other 
fusions; EspF1-20Nb, Tir1-20Nb, and NleF1-20Nb nanobody fusions were examined in WT C. 
rodentium NleB and its mutant, C. rodentium NleB DAD221-223/AAA, before and after 
precipitation. No secretion of the nanobody fusions was observed when examining their protein 
abundance after precipitation. This concluded that the 20 AA signal sequence from effectors 
EspF, Tir, NleB2, NleC, NleD, NleF, and NleH1 fused upstream at the N-terminus of the 
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nanobody does not promote secretion through the bacterial T3SS. Since the nanobodies fused to 
the 20 AA signal sequence of effectors were not secreted, translocation was not examined. 
Further studies are needed to fully understand the roles of both glycosylation of bacterial 
substrates inside the bacterium by NleB (Chapter 2) and of the secretion of effector AA signal 
sequence fusion to nanobodies, or another protein that may work better than the nanobody, 
through the T3SS (Chapter 3). For the first part of the set of studies, more bacterial substrates 
can be tested from the mass spectrometry list of arginine amino acid residue hits. The various 
changes on the functions that NleB glycosylation causes inside the bacterium would also be 
worthwhile to explore in future experiments, as our experiments did not get this far due to the in 
vivo results. For the second part of the set of studies, it is presumed that the number of proteins 
translocated by the T3SS is underestimated, and more studies of other possible secretion 
substrates would have to be conducted as there may be a better protein for fusion and secretion 
through the T3SS. It should also be noted that in our experiments, only a 20 AA signal sequence 
from the effectors was utilized. It would be beneficial to take the same effectors with the Gram-
negative bacteria tested and fuse the whole signal sequence of the effector to the nanobody to see 
if translocation through the T3SS is possible. This idea was brought forth in the studies of 
Charpentier and Oswald (2004) when it was stated that the whole effector sequence fused to the 
protein seemed to secrete the fusion more efficiently than with the 20 AA signal sequence fusion. 
Further studies should be completed with the EspF and Tir 20 AA signal sequences fused to 
TEM-1 -lactamase as a positive control since it has been proven to be secreted through a T3SS 
and it was not added in our experiments. Lastly, more experiments should also be performed to 
identify other T3SS effector substrates, as this would introduce new areas of investigation and 
aid in our understanding of EHEC and EPEC-mediated diseases. 
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Overall, the work completed in this thesis indicates that, with more research and positive 
results, these ideas have the potential to reduce the prevalence of E. coli and S. enterica in our 
society. By using the strategies listed in this thesis, the possibility of either targeting and 
inhibiting glycosylation through NleB of proteins inside the bacterium or targeting NleB directly 
inside the host cell through inhibitor protein fusions remains intact. If the studies with these two 
ideas were successful, they would show the second evidence of protein glycosylation inside the 
bacterium and the first evidence of nanobody fusions being secreted and translocated to inhibit 
NleB. However, since neither of these ideas were successful and with the confirmation that 
glycosylation within the bacterium is possible, future studies are needed. Ultimately, these 
studies bring us one step closer toward designing effective treatment and prevention strategies 
against food-borne pathogens.  
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Appendix A - NleB Glycosylation of Proteins Plasmids and Strains 
Table 1 Plasmids and strains used in Chapter 2. 
Plasmids Relevant Features Source/ 
Reference 
FLAG-NleB (C. rodentium) WT C. rodentium used for electroporation Gao et al. 
(2013) 
FLAG-NleB (C. rodentium) 
(DAD221-223/AAA) 
Mutant C. rodentium used for 
electroporation 
Gao et al. 
(2013) 
pFlag-CTC Cloning plasmid for in vivo analysis This study 
pET-28a Cloning plasmid for in vitro analysis This study 
His-FADD HisTagged FADD, positive control for in 
vitro assays 
Qaidi et 
al. (2020) 
FLAG-FADD (H. sapiens) WT FADD x pFLAG-CTC This study 
FLAG-FADD(R117A) (H. 
sapiens) 
FADD(R117A) x pFLAG-CTC This study 
FLAG-GAPDH (H. sapiens) WT GAPDH x pFLAG-CTC This study 
FLAG-GAPDH(R197A/R200A) 
(H. sapiens) 
GAPDH(R197A/R200A) x pFLAG-CTC This study 
FLAG-TRADD (H. sapiens) WT TRADD x pFLAG-CTC This study 
FLAG-TRADD(R235A) (H. 
sapiens) 
TRADD(R235A) x pFLAG-CTC This study 
His-MinC WT MinC HisTagged x pET-28a This study 
His-MinC(R107A) MinC(R107A) HisTagged x pET-28a This study 
FLAG-MinC (C. rodentium) WT MinC x pFLAG-CTC This study 
FLAG-MinC(R107A) (C. 
rodentium) 
MinC(R107A) x pFLAG-CTC This study 
His-FklB WT FklB HisTagged x pET-28a This study 
His-FklB(R129A) FklB(R129A) HisTagged x pET-28a This study 
FLAG-FklB (C. rodentium) WT FklB x pFLAG-CTC This study 
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FLAG-FklB(R129A) (C. 
rodentium) 
FklB(R129A) x pFLAG-CTC This study 
Strains   
C. rodentium DBS100 Electroporation strain for in vivo assays Qaidi et 
al. (2020) 
C. rodentium DBS100 DnleB Electroporation strain for in vivo assays Gao et al. 
(2013) 
C. rodentium DBS100 
DnleB/pFLAG-CTC-nleB 
Electroporation strain for in vivo assays Gao et al. 
(2013) 
C. rodentium gshB/pFLAG-CTC 
gshB 
Positive control for in vivo assays Gao et al. 
(2013) 
C. rodentium gshB/pFLAG-CTC 
gshB(R256A) 
Negative control for in vivo assays Qaidi et 
al. (2020) 
C. rodentium/FLAG-FADD WT FADD x pFLAG-CTC/C. rodentium This study 
C. rodentium/FLAG-
FADD(R117A) 
FADD(R117A) x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-GAPDH WT GAPDH x pFLAG-CTC/C. rodentium This study 
C. rodentium/FLAG-
GAPDH(R197A/R200A) 
GAPDH(R197A/R200A) x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-TRADD WT TRADD x pFLAG-CTC/C. rodentium This study 
C. rodentium/FLAG-
TRADD(R235A) 
TRADD(R235A) x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium minC/FLAG-minC WT MinC x pFLAG-CTC/C. rodentium This study 
C. rodentium minC/FLAG-
minC(R107A) 
MinC(R107A) x pFLAG-CTC/C. rodentium This study 
C. rodentium fklB/FLAG-fklB WT FklB x pFLAG-CTC/C. rodentium This study 
C. rodentium fklB/FLAG-
fklB(R129A) 
FklB(R129A) x pFLAG-CTC/C. rodentium This study 
S. enterica Electroporation strain for in vivo assays Qaidi et 
al. (2020) 
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E. coli BL21(DE3) x pET-28a-
minC 
MinC strain used for protein purification and 
in vitro analysis 
This study 
E. coli BL21(DE3) x pET-28a-
minC(R107A) 
MinC(R107A) strain used for protein 
purification and in vitro analysis 
This study 
E. coli BL21(DE3) x pET-28a-
fklB 
FklB strain used for protein purification and 
in vitro analysis 
This study 
E. coli BL21(DE3) x pET-28a-
fklB(R129A) 
FklB(R129A) strain used for protein 
purification and in vitro analysis 
This study 
E. coli BL21(DE3) x pET-42a-
nleB 
Active NleB for in vitro assays Qaidi et 
al. (2020) 
E. coli BL21(DE3) x pET-42a-
nleB DAD221-223/AAA 
Inactive NleB for in vitro assays Qaidi et 
al. (2020) 
E. coli BL21(DE3) x pET42a-
nleB1 (EHEC) 
Electroporation for in vivo assays El Qaidi 
et al. 
(2017) 
E. coli BL21(DE3) x pET42a-
nleB1 (EPEC) 
Electroporation for in vivo assays El Qaidi 
et al. 
(2017) 
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Appendix B - Nanobody Fusion Secretion Plasmids and Strains 
Table 2 Plasmids and strains used in Chapter 3. 
Plasmids Relevant Features/ Genotype Source/ 
Reference 
FLAG-NleB (C. rodentium) WT C. rodentium used for 
electroporation 
Gao et al. (2013) 
Residues 1-20 of EspF fused to 
Nanobody 1 
EspF1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of EspF fused to 
Nanobody 2 
EspF1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of EspF fused to 
Nanobody 5 
EspF1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of EspF fused to 
Nanobody 13 
EspF1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of EspF fused to 
Nanobody 14 
EspF1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of Tir fused to 
Nanobody 2 
Tir1-20-NB x pFLAG-CTC Charpentier et al. 
(2004), This study 
Residues 1-20 of NleB2 fused 
to Nanobody 2 
NleB21-20-NB x pFLAG-CTC This study 
Residues 1-20 of NleC fused to 
Nanobody 2 
NleC1-20-NB x pFLAG-CTC This study 
Residues 1-20 of NleD fused to 
Nanobody 2 
NleD1-20-NB x pFLAG-CTC This study 
Residues 1-20 of NleF fused to 
Nanobody 2 
NleF1-20-NB x pFLAG-CTC This study 
Residues 1-20 of NleH1 fused 
to Nanobody 2 
NleH11-20-NB x pFLAG-CTC This study 
Strains   
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C. rodentium DBS100 Electroporation strain for in vivo 
assays 
Qaidi et al. (2020) 
C. rodentium DBS100 DnleB Electroporation strain for in vivo 
assays 
Gao et al. (2013) 
WT Synthetic Injector E. coli 
(SIEC) 
Electroporation strain for in vivo 
assays 
Dr. Ramon 
(collaborator) 
Mutant Synthetic Injector E. 
coli (SIEC P1) 
Electroporation strain for in vivo 
assays 
Dr. Ramon 
(collaborator) 
C. rodentium/FLAG-EspF1-20-
NB Nanobody 2 
EspF1-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-Tir1-20-NB 
Nanobody 2 
Tir1-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-NleB21-20-
NB Nanobody 2 
NleB21-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-NleC1-20-
NB Nanobody 2 
NleC1-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-NleD1-20-
NB Nanobody 2 
NleD1-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-NleF1-20-
NB Nanobody 2 
NleF1-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
C. rodentium/FLAG-NleH11-20-
NB Nanobody 2 
NleH11-20-NB x pFLAG-CTC/C. 
rodentium 
This study 
 
